Phathom Pharmaceuticals, Inc.
PHAT
$12.56
$0.030.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 1.25% | 16.32% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1.25% | 16.32% | |||
| Cost of Revenue | 56.85% | 23.55% | |||
| Gross Profit | -7.27% | 15.29% | |||
| SG&A Expenses | 11.66% | -6.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.16% | -1.95% | |||
| Operating Income | -161.08% | 61.18% | |||
| Income Before Tax | -43.60% | 29.44% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -43.60% | 29.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -43.60% | 29.44% | |||
| EBIT | -161.08% | 61.18% | |||
| EBITDA | -164.95% | 61.63% | |||
| EPS Basic | -29.18% | 29.85% | |||
| Normalized Basic EPS | -29.15% | 29.82% | |||
| EPS Diluted | -29.18% | 29.85% | |||
| Normalized Diluted EPS | -29.15% | 29.82% | |||
| Average Basic Shares Outstanding | 11.15% | 0.57% | |||
| Average Diluted Shares Outstanding | 11.15% | 0.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||